How to Localize Labels and Instructions for Medical Device Registration in Thailand?

Medical device registration in Thailand typically requires first confirming the product classification and applicable pathway, then preparing technical files, labels and instructions, quality system evidence, authorization documents, and local representative information. Existing NMPA documents can serve as a basis, but they usually need to be adapted for language, format, labeling, and evidence chain in accordance with Thai FDA (TFDA) requirements.

Published: 2026-07-10 11:45 Updated: 2026-07-10 11:45

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documents and Evidence
• Common Errors
• Company Preparation Checklist
• Aimeili Viewpoint
• Frequently Asked Questions
• Further Reading
• Applicable Boundaries

Key Summary

For Chinese medical device manufacturers, a more reliable approach is to first conduct product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documents can be reused. Registration in Thailand typically affects technical files, authorized representative, importer cooperation, labeling language, quality system evidence, and subsequent change maintenance. If the process is driven only by 'which documents to submit' in the early stage, it is easy to encounter deficiency letters or rework in terms of model coverage, evidence chain consistency, labeling claims, and certificate control.

Aimeili recommends that companies incorporate this issue into a unified planning for GHWP member states and multi-country market access strategies, using a reusable core technical file to support localization in different markets, rather than redoing documents on an ad hoc basis for each country. Companies should also make project-based judgments in light of the latest requirements of the target country's regulatory authority, the existing technical file basis, product risk level, and launch plans, avoiding mechanical preparation based solely on a document checklist.

Compiled based on Aimeili's regulatory practice question bank, medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be subject to the latest requirements of the target country's regulatory authority and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for 'how to localize labels and instructions for medical device registration in Thailand' are usually not looking for a conceptual explanation. They want to determine whether existing documents can support a Thai submission, whether a local agent or authorized representative is needed, why timelines may be extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for only one country is not enough. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels/instructions, and then adapt them locally according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method of body contact, duration of use, whether it is sterile, whether it is active, and whether it contains software or IVD attributes, and then determine the risk class and submission pathway. Once the pathway judgment is wrong, subsequent translation, notarization, authorization, testing, and supplementary documents will all deviate from the correct direction.

For Thai projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documents. If these issues are handled vaguely in commercial contracts, they can easily affect market control in the later stages.

Documents and Evidence

Common documents include product description, model specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management documents, clinical evaluation or clinical evidence, labels and instructions, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documents.

The key to document quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and information on the registration application form must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

• The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Translating NMPA documents directly and submitting them without rearranging evidence according to the Thai pathway.
• Too many model specifications, but insufficient coverage in test reports, clinical evidence, or labeling.
• Selecting a local agent solely based on sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistencies in claims among labels, instructions, promotional materials, and registration documents, leading to deficiency letters or post-market compliance risks.
• Failure to plan for multi-country document reuse in advance, leading to repeated preparation for each country and inflated costs and timelines.

Company Preparation Checklist

• Compile a list of target products, model specification matrix, and intended use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions.
• Confirm the responsibilities, fees, certificate control, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table to identify what needs additional testing, translation, notarization, or supplementary declarations.

Aimeili Viewpoint

Aimeili recommends that companies do not view Thai registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear set of core technical files and an evidence matrix first, and then converting them according to each country's requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than preparing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the document evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are not clear, even if the documents appear numerous, the project may still encounter repeated issues during deficiency responses, agent communication, and post-market maintenance.

Frequently Asked Questions

Can domestic (NMPA) documents be used directly for Thai registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labeling adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities usually check whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the declared product, or if the manufacturing address, model specifications, or instructions version are inconsistent with test reports, the company may be asked for supplementary explanations even if it has prepared a large number of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labels/instructions version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiency letters, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product series.

Localization and Agent Responsibilities

Thai registration projects typically involve local agents, authorized representatives, importers, or registration holders. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions, and authorization documents cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest a lot of effort in obtaining certificates but neglect post-market maintenance. Once there is a change in manufacturing address, model expansion, instructions update, or agent replacement, the certificate and market sales can easily become disconnected.

Aimeili recommends that companies incorporate this issue into annual international registration plan management: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only to improve registration efficiency in a single country, but more importantly, to enable companies to develop a replicable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

Previous: How to Organize Technical Files for Medical Device Registration in Thailand?

Next: How to Prepare Clinical Evaluation Documents for Medical Device Registration in Thailand?

Recommended Reading:

• How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• How to Determine Product Classification for Medical Device Registration in Malaysia?
• How to Organize Technical Files for Medical Device Registration in Malaysia?
• How to Localize Labels and Instructions for Medical Device Registration in Malaysia?
• How to Prepare Clinical Evaluation Documents for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Content Review and Applicable Boundaries

Content author: Aimeili Regulatory Editorial Team

Professional review: Aimeili Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as supplementary references.

Applicable boundaries: This article is intended for preliminary understanding, document preparation, and project planning, and does not replace the official requirements of the target country's regulatory authority, test conclusions, or legal advice.